Anthrax Vaccine: New Developments


Pending
Written on - Not yet published to a wikizine
Anthrax... So you haven't heard about the vaccine for a while; is the threat of bioterrorism still real? VaxGen, Inc. a biopharmaceutical company, announced today it has completed the sale of all assets and rights related to its recombinant protective antigen (rPA) anthrax vaccine product candidate and related technology to Emergent BioSolutions, Inc. Emergent BioSolutions paid VaxGen $2 million
More From This Author